carfilzomib + prednisone

Carfilzomib + prednisone is a **combination chemotherapy regimen** consisting of carfilzomib, a proteasome inhibitor, and prednisone, a synthetic glucocorticoid corticosteroid. **Carfilzomib selectively inhibits the 20S proteasome**, leading to disrupted protein homeostasis, accumulation of unwanted proteins, and apoptosis of cancer cells, particularly in multiple myeloma[3][1]. **Prednisone exerts immunosuppressive and anti-inflammatory effects**, and is commonly used in oncology regimens to enhance apoptosis or mitigate adverse effects. This combination is mainly investigated for **multiple myeloma**, with clinical studies emphasizing its use in elderly or transplant-ineligible patients[1][6]. Carfilzomib is developed by Amgen and marketed under the brand name Kyprolis, primarily administered intravenously, while prednisone is taken orally.

Other names

carfilzomib + prednisone